Twitter | Pretraživanje | |
mk
1.011
Tweetovi
330
Pratim
28
Osobe koje vas prate
 
Prikaži više fotografija
Tweetovi
mk proslijedio/la je tweet
Brad Loncar 20 h
Yescarta sales
Prikaz fotografije · Reply Retweet Označi sa "sviđa mi se"
mk proslijedio/la je tweet
steve usdin 4. velj
Gilead preparing a trial in China of remdesivir to treat 2019-nCoV: . Meanwhile, at least 9 trials of #2019-nCoV therapies are underway. All BioCentury coverage of the outbreak is in front of the paywall at .
Prikaz fotografije · Reply Retweet Označi sa "sviđa mi se"
mk proslijedio/la je tweet
Peter B. Bach, MD 29. sij
Odgovor korisniku/ci @NEJM @DhruvKhullar
And here is a sample of 3 policies we describe and how they alter the Reward Box shape and thus the risk and reward of developing particular types of drugs:
Prikaz razgovora · Reply Retweet Označi sa "sviđa mi se"
mk proslijedio/la je tweet
Bertrand Delsuc 30. sij
Number of patients treated w/ CAR-Ts in Europe (commercial vs academic)
Prikaz fotografije · Reply Retweet Označi sa "sviđa mi se"
mk proslijedio/la je tweet
Eric Topol 30. sij
A prime example of a great explainer for a complex topic: my brilliant friend , aka Gene Editor, explains genome editing and search-and-replace (prime) editing re:
Prikaz fotografije · Reply Retweet Označi sa "sviđa mi se"
mk proslijedio/la je tweet
Nature Rev Drug Disc 29. sij
Matthew Disney is talking about how to approach RNA as a target for small-molecule probes and drugs at - here's a perspective with more on this topic
Prikaz fotografije · Reply Retweet Označi sa "sviđa mi se"
mk proslijedio/la je tweet
Zach Brennan 28. sij
Humira biosimilars now controlling almost 40% of the market in the EU, according to Bernstein. The UK and Germany are outpacing the others... ...and the US looks on in shame, swallowing another 7.4% price increase from AbbVie for 2020
Prikaz fotografije · Reply Retweet Označi sa "sviđa mi se"
mk proslijedio/la je tweet
Adam J. Fein 28. sij
Biosimilar competition update: is launching its 3 at WAC list prices of -22% to -24% below competitors' products Open question: Will , , and embrace or block lower price ?
Prikaz sažetka · Reply Retweet Označi sa "sviđa mi se"
mk proslijedio/la je tweet
SY Investing 28. sij
The FDA finalized 6 guidance documents on development about: - - - Retinal disorders - CMC for INDs - LT follow-up - Retrovirus testing Also released new draft guidance on interpreting the sameness of gene therapies.
Prikaz sažetka · Reply Retweet Označi sa "sviđa mi se"
mk proslijedio/la je tweet
Peter Kolchinsky 28. sij
I can see how this makes it a lot easier to read. Thank you for assembling.
Prikaži podatke · Reply Retweet Označi sa "sviđa mi se"
mk proslijedio/la je tweet
Barack Obama 26. sij
Kobe was a legend on the court and just getting started in what would have been just as meaningful a second act. To lose Gianna is even more heartbreaking to us as parents. Michelle and I send love and prayers to Vanessa and the entire Bryant family on an unthinkable day.
Prikaži podatke · Reply Retweet Označi sa "sviđa mi se"
mk proslijedio/la je tweet
ct 26. sij
Given there will be a big need for many biotech's to raise this year & January 2020 broke an all-time record for total amount raised & # of Co's that raised in Jan, I put together a list (far from perfect) of bio companies that have < 2 years of cash based on estimates.
Prikaz fotografije · Reply Retweet Označi sa "sviđa mi se"
mk proslijedio/la je tweet
Jacob Plieth 22. sij
Woodcock to Unger to Stein, or how scored its FDA double play. Via
Prikaz sažetka · Reply Retweet Označi sa "sviđa mi se"
mk proslijedio/la je tweet
Nature Rev Drug Disc 22. sij
Neutrophils as emerging therapeutic targets in infection, pulmonary diseases, cardiovascular diseases, inflammatory disorders and cancer - a new review published today
Prikaz fotografije · Reply Retweet Označi sa "sviđa mi se"
mk proslijedio/la je tweet
Andy Biotech 22. sij
Very underwhelming data for anti-CD47 magrolimab + cetuximab combo in colorectal cancer 6.7% (2/30) ORR in KRAS wild type CRC 0% (0/40) ORR in KRAS mutant CRC
Prikaži podatke · Reply Retweet Označi sa "sviđa mi se"
mk proslijedio/la je tweet
John Carroll 17. sij
Loved this story from -- At , two CEOs, two radically different therapies, and a fight to chase down sickle cell
Prikaz sažetka · Reply Retweet Označi sa "sviđa mi se"
mk proslijedio/la je tweet
Andy Biotech 13. sij
Just amazing people are still falling for these "response" from their miracle sextuple combo How the hell do you run a controlled trial to convince FDA about the real effect of your drug?
Prikaz fotografije · Reply Retweet Označi sa "sviđa mi se"
mk proslijedio/la je tweet
Andy Biotech 16. sij
Three important new papers today demonstrate that the presence of B cells in tertiary lymphoid structures (TLS) is associated with a favorable response to cancer
Prikaz fotografije · Reply Retweet Označi sa "sviđa mi se"
mk proslijedio/la je tweet
NatureReviewsCancer 15. sij
Our NEW Review by Vishwakarma & Piddini discusses how cell competition between tumour cells & neighbouring epithelial host cells may dictate tumorigenesis & proposes manipulating cell competition as an orthogonal therapeutic strategy
Prikaz fotografije · Reply Retweet Označi sa "sviđa mi se"
mk proslijedio/la je tweet
Cancer Cell 15. sij
This Is Our Cells Under Pressure: Decreased DNA Damage Repair in Response to Targeted Therapies Facilitates the Emergence of Drug-Resistant Clones
Prikaz fotografije · Reply Retweet Označi sa "sviđa mi se"
Učitaj starije tweetove